--Reached Agreement with
Tadalafil (CIALIS®) is currently approved for treatment of BPH and erectile dysfunction and finasteride is currently approved for treatment BPH (finasteride 5mg PROSCAR®) and male pattern hair loss (finasteride 1mg PROPECIA®). The co-administration of tadalafil and finasteride has been shown to be more effective for the treatment of BPH than by finasteride alone.
The Company's commercial products include the FC2 Female Condom / FC2 Internal Condom® ("FC2"), an
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
Press Release Kari Sharp